
Please try another search
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
John J. Alam | 62 | 2023 | Co-Founder, CEO, President & Director |
Joshua S. Boger | 73 | 2024 | Independent Chair of the Board |
Sylvie L. Gregoire | 64 | 2023 | Co-Founder & Director |
Ole Isacson | 64 | - | Chair of the Scientific Advisory Board |
Marwan Noel Sabbagh | 59 | 2023 | Independent Non-Executive Director |
Jeffrey V. Poulton | 57 | 2023 | Independent Director |
Jeffrey L. Cummings | 75 | - | Member Scientific of Advisory Board |
Heidi McBride | - | - | Member of Scientific Advisory Board |
Lewis clayton Cantley | 76 | - | Member of Scientific Advisory Board |
Frank E. Zavrl | 59 | 2023 | Independent Director |
Jane Holmes Hollingsworth | 66 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review